Introduction
============

Melanoma is a tumor that originates in melanocytes of the skin or other parts of the body ([@b1-ol-0-0-10961]). The main function of melanocytes is to produce melanin via melanogenesis, a multistep biochemical process regulated by L-tyrosine, L-DOPA and other hormones ([@b2-ol-0-0-10961],[@b3-ol-0-0-10961]). Melanogenesis leads to the upregulation of hypoxia-inducible factor 1, which modulates the cellular metabolism of melanoma ([@b4-ol-0-0-10961]). A previous study has demonstrated that pigmentation level is associated with the overall and disease-free survival time of patients with stage III and IV melanoma ([@b5-ol-0-0-10961]). In the United States, \>91,000 individuals were diagnosed with cutaneous melanoma in 2018, and \>9,000 patients succumbed to the disease in the same period ([@b6-ol-0-0-10961]). Since melanoma tends to spread lymphogenously and hematogenously, patients with inoperable metastatic melanoma exhibit median survival times between 8 and 12 months ([@b7-ol-0-0-10961]). Therefore, melanoma poses a serious threat to life.

Gene mutations in melanoma may activate multiple signaling pathways that regulate proliferation, epithelial-mesenchymal transition, invasion and metastasis in an abnormal manner ([@b8-ol-0-0-10961]). For example, BRAF mutations, predominantly V600E, occur in 40--50% of all melanomas, whereas NRAS proto-oncogene, GTPase and neurofibromin 1 mutations occur in \~20 and 15% of melanomas, respectively ([@b9-ol-0-0-10961]). Targeted therapy and immunotherapy have been demonstrated to be effective treatment methods ([@b10-ol-0-0-10961],[@b11-ol-0-0-10961]). BRAF/mitogen-activated protein kinase kinase inhibitors, as well as antibodies against cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 have been used for treatment of metastatic melanoma, with patient response rates ranging between 20 and 70% ([@b12-ol-0-0-10961]). Although these breakthrough treatments have prolonged progression-free survival to a certain extent, drug resistance still limits their effectiveness ([@b13-ol-0-0-10961]). For example, immune-based therapy is subject to limitations, such as the prevention of the generation of an immunosuppressive environment ([@b14-ol-0-0-10961]). Therefore, there remains a need for novel markers of prognosis and novel therapeutic drugs for melanoma.

Weighted gene co-expression network analysis (WGCNA) is widely used to analyze genetic expression data, locate modules of highly correlated genes and identify potential biomarkers, as well as therapeutic targets. Thus, the present study aimed to utilize WGCNA to identify novel biomarkers associated with melanoma prognosis. Additionally, the present study aimed to determine the proximity between disease-associated proteins and drug targets in the human protein-protein interactome in order to identify potential drugs for the treatment of melanoma.

Materials and methods
=====================

### Data processing

Melanoma transcriptome dataset GSE65904 ([@b15-ol-0-0-10961]) was downloaded from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo>). GSE65904 comprised 214 samples from patients with melanoma, no non-tumor tissue samples or healthy subjects were included. Illumina HumanHT-12V4.0 expression beadchip was used as the sequencing platform. Clinical information of patients, including sex, age, tumor stage, distant metastasis and survival state, was collected. The GEO query package in R v2.52.0 (<https://git.bioconductor.org/packages/GEOquery>) was used to process the data. If the expression of a gene was not significant compared with the background value (standard probe) in \>25% of all samples (P\>0.05), the probe was removed from further analysis. A total of 10,566 genes were obtained.

### Weighted co-expression network construction

The top 50% most differentially expressed genes (5,283 genes) were selected for WGCNA analysis following analysis of variance using R 3.3.2 (<https://www.r-project.org/>) ([@b16-ol-0-0-10961]). These genes were used for screening and cluster analysis of all samples, as well as to identify outliers, following which one patient was removed from the study ([Fig. 1](#f1-ol-0-0-10961){ref-type="fig"}). The gene expression data of the patients was used to construct the co-expression network, and the WGCNA algorithm was utilized for analysis ([@b16-ol-0-0-10961]). To ensure that the nodes of the constructed co-expression network conformed to the power rate distribution, appropriately soft threshold was selected (β=3), which enabled the deletion of low mutual correlation relationships. The distribution of network nodes conformed to the power rate distribution at β=3. Further investigation of the distribution of node degrees in the co-expression network revealed that the degree of nodes conformed to the power law distribution. This indicated that the constructed co-expression network was a scale-free network, conforming to the characteristics of common biological networks. The average linkage hierarchical clustering method ([@b17-ol-0-0-10961]) was used to cluster all genes.

### Identification of clinically significant modules

To obtain the gene modules that were associated with clinical phenotypes, the correlation between modules and clinical phenotypes was determined. Module eigengenes (MEs) were considered as characteristics of all genes in a certain module. The association between MEs and clinical characteristics was analyzed to determine a clinically significant module for further use.

### Gene Ontology (GO) and pathway enrichment analysis

The ClusterProfiler package (<https://github.com/GuangchuangYu/clusterProfiler>) in R v3.12.0 was used to determine the functions of the enriched genes from the two modules in [Fig. 3](#f3-ol-0-0-10961){ref-type="fig"} (black and turquoise modules) in GO ([@b18-ol-0-0-10961]) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b19-ol-0-0-10961]) pathway analysis, respectively. Genes in the clinically significant module were categorized into three functional groups: Biological process (BP), cellular component (CC) and molecular function (MF).

### Identification and validation of hub genes

To identify genes associated with melanoma prognosis, the association between each gene and clinical characteristics was evaluated, as well as the association between each gene and core modules, such as module membership (MM) and gene significance (GS). MM is defined by the correlation between the gene expression profile and MEs, whereas GS is defined by the association between a gene and external traits. Genes with \|MM+GS\|=5% in the aforementioned modules (black and turquoise modules) in [Fig. 3](#f3-ol-0-0-10961){ref-type="fig"} were selected as potentially prognostic genes; all other genes were removed. To further analyze the association between these genes, the remaining candidate genes were input into STRING (<https://string-db.org/>) to construct a protein-protein interaction (PPI) network using Cytoscape v3.2 ([@b20-ol-0-0-10961]).

To verify whether the identified genes were associated with tumor progression and prognosis, the association between each gene and survival was determined using the R survival package v2.41-3 (<https://cran.r-project.org/web/packages/survminer/index.html>). Clinical and RNA-sequencing data from 417 patients with melanoma were downloaded from The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>) using the TCGA biolinks package in R v2.12.3 (<https://git.bioconductor.org/packages/TCGAbiolinks>). Overall survival was analyzed using the log-rank test. In addition, the ggpubr package v0.2.1 (<http://cran.r-project.org/web/packages/ggpubr/index.html>) was used to demonstrate the mRNA expression of hub genes in primary and metastatic tumor, and the two groups were compared by Student\'s t-test. Receiver operating characteristic (ROC) curve and area under the curve (AUC) values were obtained using the pROC package v1.15.0 (<http://cran.r-project.org/web/packages/ROCR>) to evaluate the efficiency of the genes in distinguishing metastatic and non-metastatic tumors.

### Screening candidates for treatment

Drug-target information of Food and Drug Administration (FDA)-approved drugs was obtained from DrugBank (<https://www.drugbank.ca/>). The exclusion of drugs that had no known targets in the interactome resulted in a total of 1,269 unique drugs and 1,185 targets selected for further analysis. Notably, only pharmacological targets ('Targets' section in DrugBank), excluding enzymes, carriers and transporters typically shared among different drugs, were considered. The protein interaction information was obtained from a previously published study, which contained data from 15 databases ([@b21-ol-0-0-10961]). Among these, 15,969 nodes and 217,160 mutual relationships were identified in the PPI networks. The prognostic genes of melanoma were mapped to the PPI network. The Igraph package v1.2.4.1 (<https://igraph.org/>) was used to estimate the shortest distance between each target and a particular prognostic gene for each FDA-approved drug ([@b21-ol-0-0-10961]). Standardization-based approximation indicated that lower values were associated with an increased likelihood that the drug may act on melanoma and prevent its progression.

Results
=======

### Weighted co-expression network construction and key module identification

Following a cluster analysis of all samples, one sample in GSE65904 was removed from subsequent analysis due to bias ([Fig. 1](#f1-ol-0-0-10961){ref-type="fig"}; [Table I](#tI-ol-0-0-10961){ref-type="table"}). To ensure a scale-free network, it must satisfy R^2^\> 0.8 ([Fig. 2A](#f2-ol-0-0-10961){ref-type="fig"}), and the mean connectivity should be conserved as much as possible ([Fig. 2B](#f2-ol-0-0-10961){ref-type="fig"}). Furthermore, the degree distribution of nodes in the co-expression network was investigated further and the degree of nodes conforms to power law distribution ([Fig. 2C and D](#f2-ol-0-0-10961){ref-type="fig"}). The WGCNA package in R was used to place genes with similar expression patterns into modules through average linkage clustering; a total of 15 modules were identified ([Fig. 3A](#f3-ol-0-0-10961){ref-type="fig"}). The black module exhibited the strongest association with tumor metastasis-free survival and disease-specific death survival ([Fig. 3](#f3-ol-0-0-10961){ref-type="fig"}), whereas the turquoise module exhibited the strongest association with tumor stage. Therefore, these two modules were considered to be clinically significant and were selected for further analysis.

### GO and KEGG pathway enrichment analysis

The genes in the clinically significant modules were categorized into functional groups: BP, CC and MF. The genes in the black module were mainly enriched in 'antigen processing and presentation', 'antigen processing and presentation of peptide antigen' and 'antigen processing and presentation of exogenous peptide antigen' in the BP group, 'endocytic vesicle membrane', 'Golgi-associated vesicle' and 'COPII-coated ER to Golgi transport vesicle' in the CC group, and 'amide binding', 'peptide binding' and 'antigen binding' in the MF group ([Fig. 4A](#f4-ol-0-0-10961){ref-type="fig"}). The results of the KEGG pathway analysis demonstrated that genes in the black module were mainly involved in 'antigen processing and presentation', 'viral myocarditis', 'cell adhesion molecules cams' and 'allograft rejection', among others ([Fig. 5A](#f5-ol-0-0-10961){ref-type="fig"}).

The genes in the turquoise module were mainly enriched in 'leukocyte differentiation', 'T cell activation' and 'regulation of lymphocyte activation' in the BP group, 'cell leading edge', 'lamellipodium' and 'cytoplasmic side of plasma membrane' in the CC group and 'nucleoside-triphosphatase regulator activity', 'GTPase regulator activity' and 'phospholipid binding' in the MF group ([Fig. 4B](#f4-ol-0-0-10961){ref-type="fig"}). The results of the KEGG pathway analysis demonstrated that the genes in the turquoise module were mainly involved in 'chemokine signaling pathway', 'B cell receptor signaling pathway' and 'T cell receptor signaling pathway', among others ([Fig. 5B](#f5-ol-0-0-10961){ref-type="fig"}).

### Identification and validation of hub genes

Genes with \|MM+GS\|=5% in the black and turquoise modules were selected as candidate prognostic genes, and all other genes were removed. A PPI network of all genes in the black and turquoise modules was constructed using Cytoscape. The network comprised 222 nodes and 1,416 edges according to the STRING database ([Fig. 6](#f6-ol-0-0-10961){ref-type="fig"}). Among those, C-X-C motif chemokine receptor 4 (CXCR4), interleukin 7 receptor (IL7R) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit γ (PIK3CG) were positively associated with overall survival ([Fig. 7D-F](#f7-ol-0-0-10961){ref-type="fig"}). Based on TCGA data, the expression levels of CXCR4, IL7R and PI3KG were upregulated in primary tumors compared with metastatic tumors ([Fig. 7A-C](#f7-ol-0-0-10961){ref-type="fig"}). In addition, the ROC curves indicated that CXCR4, IL7R and PI3KG exhibited excellent efficacy for diagnosing primary and metastatic tumor tissues ([Fig. 7G-I](#f7-ol-0-0-10961){ref-type="fig"}).

### Screening candidates for treatment

Using genes which were identified as hub nodes in the PPI network (degree \>30) associated with prognosis (P\<0.05) and metastasis (AUC \>0.7) as potential targets in the drug-gene interaction analysis ([Fig. 8](#f8-ol-0-0-10961){ref-type="fig"}), the top 15 drugs ranked by the proximity of genes and drugs were screened as possible treatments for melanoma. The screened drugs could be divided into several major categories, including tyrosine kinase inhibitors (TKIs), vascular endothelial growth factor receptor (VEGFR) inhibitors, estrogen receptor modulators, proteasome inhibitors, Burton\'s tyrosine kinase (BTK) inhibitors and Raf kinase inhibitors. The top 15 drugs are: Ponatinib, nintedanib, tamoxifen, framycetin, regorafenib, dasatinib, sunitinib, bosutinib, benzylpenicilloyl polylysine, ibrutinib, pazopanib, methyl aminolevulinate, bortezomib, sorafenib, lenvatinib.

Discussion
==========

Among skin tumors, melanoma is the most malignant ([@b22-ol-0-0-10961]). High recurrence and metastasis rates affect the efficacy of melanoma treatment ([@b23-ol-0-0-10961]). The effects of conventional chemotherapy, immunotherapy and targeted therapy remain limited. Thus, identifying novel molecular targets and exploring therapeutic drugs for melanoma is important. In the present study, the GEO database was used to obtain genetic and clinical information from patients with melanoma, construct a co-expression network, select the most significant module and identify three hub genes: CXCR4, IL7R and PIK3CG. TCGA, which was used for further verification, revealed that three aforementioned specific molecules: CXCR4, IL7R and PIK3CG identified in melanoma tissues were associated with prognosis and metastasis. In addition, the top 15 drugs ranked by the proximity of genes and drugs were screened using a network screening method, and a drug-gene network was constructed.

CXCR4, which is a receptor of C-X-C motif chemokine 12 (CXCL12), is located on the surface of \>23 human tumors, for example breast cancer, ovarian cancer, glioma, pancreatic cancer and prostate cancer ([@b24-ol-0-0-10961]). CXCL12 binds to CXCR4, which activates several extra- and intracellular signaling pathways, including the nuclear factor κB, Ca^2+^-dependent protein tyrosine kinase 2β, PI3K-Akt and mitogen-activated protein kinase signaling pathways ([@b25-ol-0-0-10961]). In various types of cancer, such as oral ([@b26-ol-0-0-10961]), esophageal ([@b27-ol-0-0-10961]), gastric, colon, liver, pancreatic, thyroid and ovarian cancer ([@b28-ol-0-0-10961]), and leukemia ([@b29-ol-0-0-10961]), CXCR4 expression is strongly associated with chemotaxis, invasion, angiogenesis and cell proliferation, all of which are involved in tumorigenesis and cancer. However, the results of the present study indicated that, compared with primary tumors, CXCR4 is downregulated in metastatic tumors, and is therefore associated with good prognosis in patients with melanoma. Mitchell *et al* ([@b30-ol-0-0-10961]) demonstrated that most of melanoma cases with mitosis, ulceration and regression were CXCR4-negative. Patients with American Joint Committee on Cancer (AJCC) stage ([@b31-ol-0-0-10961]) I and II melanoma exhibit higher expression of CXCR4 compared with those with AJCC stages III and IV, and a proportion of patients with AJCC stage III--IV melanoma are CXCR4-negative ([@b30-ol-0-0-10961]). Therefore, the role of CXCR4 as a biomarker warrants further investigation.

IL7R, which is expressed in immune cells, is crucial for the survival, development and homeostasis of the immune system ([@b32-ol-0-0-10961]). IL-7Rα activates Janus kinases 1 and 3, promoting the function of signal transducer and activator of transcription 5, which leads to the modulation of gene expression, as well as the activation of anti-apoptotic and pro-survival signaling pathways ([@b33-ol-0-0-10961]). Thus, IL7R is classified as an oncogene associated with several tumors, including esophageal and prostate cancer ([@b34-ol-0-0-10961]). However, a bioinformatics study has demonstrated that patients with colon cancer lacking IL7R (two cases of mortality out of three cases) had a median survival time of 34 months compared with patients with normal IL7R status, whose survival time was 45 months ([@b35-ol-0-0-10961]). Studies on the association between IL7R and melanoma, as well as the association between IL7R and metastasis, are lacking.

The PI3K signaling pathway modulates various biological processes, including cell proliferation, survival, motility, death and metabolism ([@b36-ol-0-0-10961]). Aberrations in these processes are pivotal for the pathogenesis of cancer. Based on structural differences, PI3K can be divided into several subunits, including PIK3CA, PIK3CB, PIK3CD and PIK3CG ([@b37-ol-0-0-10961]). A previous study has revealed that PIK3CG is expressed at undetectable levels in glioblastoma cells, and that blocking this specific subunit does not cause cytotoxicity ([@b38-ol-0-0-10961]). Another study has demonstrated that PIK3CG is downregulated in colorectal cancer, whereas 12 other genes in the PI3K-AKT signaling pathway are upregulated ([@b39-ol-0-0-10961]). However, a bioinformatics-based study reported that PIK3CG is significantly associated with melanoma metastasis to regional lymph nodes, which contradicted the results of the present study, suggesting that further investigation may be required to clarify the role of PIK3CG in the metastasis of melanoma ([@b40-ol-0-0-10961]).

In the present study, the GEO database, which comprised 214 melanoma samples, and TCGA database, which included 417 patients, were selected to verify the roles of the identified genes. Double validation and a large number of samples contributed to the reliability of the candidate genes. However, a limitation of the present study was a lack of clinical or experimental validation. Further study is required to verify the role of CXCR4, IL7R and PI3K3CG in melanoma.

The analysis of the association between genes and FDA-approved drugs demonstrated that the top 15 drugs were TKIs, VEGFR inhibitors, estrogen receptor modulators, proteasome inhibitors, Bcr-Abl kinase inhibitors, BTK inhibitors, Raf kinase inhibitors, framycetin, benzylpenicilloyl polylysine and methyl aminolevulinate. TKIs that function by blocking the Bcr-Abl tyrosine-kinase included dasatinib, ponatinib and bosutinib, which are used to treat chronic myelogenous leukemia and acute lymphocytic leukemia ([@b41-ol-0-0-10961]). Other drugs, including nintedanib, regorafen, sunitinib, pazopanib, sorafenib and lenvatinib inhibit several receptor tyrosine kinases, including platelet-derived growth factors, VEGFR, fibroblast growth factor receptors and Raf family kinases, which inhibit tumor angiogenesis and tumor cell proliferation ([@b42-ol-0-0-10961]). Ibrutinib, a BTK inhibitor, is used to treat chronic lymphocytic leukemia ([@b43-ol-0-0-10961]). Tamoxifen, a selective estrogen receptor modulator, is used for the treatment and prevention of estrogen receptor-positive breast cancer ([@b44-ol-0-0-10961]). Bortezomib was the first therapeutic proteasome inhibitor to be tested in humans; it serves a role in cell cycle arrest and apoptosis, and is approved in the United States for the treatment of relapsed multiple myeloma and mantle cell lymphoma ([@b45-ol-0-0-10961]). Framycetin, which is an antibiotic, is used to treat leg ulcers and other conditions associated with wound healing ([@b46-ol-0-0-10961]). Benzylpenicilloyl polylysine is used as a skin-testing reagent for individuals with a history of penicillin allergy ([@b47-ol-0-0-10961]). Methyl aminolevulinate, which is metabolized into phototoxic compounds, such as protopophyrin IX, may represent a candidate for photodynamic therapy, as it can induce oxidative damage to the cell ([@b48-ol-0-0-10961]).

Angiogenesis is a hallmark of several types of tumor, including melanoma. The process of angiogenesis is crucial for tumor development and metastasis ([@b49-ol-0-0-10961]). VEGF is one of the most important cytokines responsible for tumor-mediated angiogenesis ([@b50-ol-0-0-10961]). VEGF is strongly expressed in melanoma and serves a critical role in the progression of the disease ([@b51-ol-0-0-10961]). In a phase II study of sunitinib in patients with advanced melanoma, 4/31 (13%) patients exhibited a partial response and 8 (26%) had stable disease ([@b52-ol-0-0-10961]). Pazopanib, a VEGF and platelet-derived growth factor inhibitor, has been used in combination with paclitaxel in a phase II study of patients with metastatic melanoma; the 6-month progression-free survival rate was 68%, and the 1-year overall survival rate was 48% ([@b53-ol-0-0-10961]). The objective response rate was 37%, comprising one complete and 20 partial responses ([@b54-ol-0-0-10961]). A phase Ib study using lenvatinib (E7080) in combination with temozolomide for the treatment of advanced melanoma indicated an overall objective response rate of 18.8% (six patients), comprising all partial responses ([@b55-ol-0-0-10961]). SRC proto-oncogene, non-receptor tyrosine kinase (SRC) is a promising target in the treatment of solid types of cancer, including human melanoma; bosutinib, a SRC inhibitor, which induces cell death via lysosomal membrane permeabilization in melanoma cells, is a promising therapeutic agent for melanoma treatment ([@b56-ol-0-0-10961]). SRC inhibitor Dasatinib specifically inhibits p53 phosphorylation in melanoma; however, a comprehensive validation is required ([@b57-ol-0-0-10961]). Ibrutinib, a BTK inhibitor, has been used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma and subsequent melanoma that occurs following leukemia ([@b58-ol-0-0-10961]). Sorafenib, a Raf inhibitor, is a first-line therapeutic agent used in advanced melanoma (phase I and open-label phase II) trials with an overall response rate of 12% with one complete response and nine partial responses ([@b59-ol-0-0-10961]). Bortezomib administration reduces the levels of proangiogenic cytokines in plasma ([@b60-ol-0-0-10961]). A clinical trial has indicated that tamoxifen therapy is not effective for treating melanoma, and that the mode of action of antiestrogens in melanoma is unclear ([@b61-ol-0-0-10961]). To the best of our knowledge, ponatinib, nintedanib, regorafen, framycetin, benzylpenicilloyl polylysine and methyl aminolevulinate have not been used to treat melanoma.

The present study used WGCNA to construct a gene co-expression network in order to determine the associations between genes and modules and to explore the association between the gene modules and clinical characteristics. Two significant modules (black and turquoise modules) shown in [Fig. 3](#f3-ol-0-0-10961){ref-type="fig"}, were identified to be associated with the progression of melanoma. GO and KEGG pathway analyses demonstrated that this module was mostly involved in functions associated with antigen presentation. In addition, three hub genes, CXCR4, IL7R and PI3K3CG, were identified and demonstrated to be associated with the progression and prognosis of melanoma. Analysis of the interaction between genes and drug targets of the top 15 drugs for melanoma enabled the construction of a network of drug-gene interactions. Ponatinib, regorafen, nintedanib, framycetin, benzyl penicilloyl polylysine and methyl aminolevulinate, which were among the 15 drugs not currently used to treat melanoma, may be potential novel therapeutic drugs for this disease.
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![Cluster dendrogram of 214 melanoma samples. The GSE65904 dataset was used. The red line indicates the outlier to rule out biased samples. The black lines represent each sample in the dataset, and the numbers represent corresponding GSM of the patient.](ol-18-06-6066-g00){#f1-ol-0-0-10961}

![Determination of soft-thresholding power in weighted gene co-expression network analysis. (A) Scale-free fit index of various soft-thresholding powers. (B) Mean connectivity of various soft-thresholding powers. (C) Histogram of connectivity distribution at β=3. (D) Scale-free topology at β=3. β, soft thresholding power; k, connectivity.](ol-18-06-6066-g01){#f2-ol-0-0-10961}

![Identification of modules associated with the progression of melanoma. (A) Dendrogram of all differentially expressed genes clustered based on a dissimilarity measure. (B) Heatmap of the association between module eigengenes and the progression of melanoma. DMFS, distant metastasis-free survival; Dss, disease-specific death survival; ME, module eigengene. The red color of each box represents the positive association between the module and trait whereas the green color of each box represents the negative associations. The association of the module and trait is calculated to be between −1 and 1.](ol-18-06-6066-g02){#f3-ol-0-0-10961}

![Gene Ontology analysis of the genes in the black and turquoise modules. (A) Gene Ontology analysis of the genes in the black module. (B) Gene Ontology analysis of the genes in the turquoise module. BP, biological process; CC, cellular component; MF, molecular function.](ol-18-06-6066-g03){#f4-ol-0-0-10961}

![KEGG analysis of the genes in the black and turquoise modules. (A) KEGG analysis of the genes in the black module. (B) KEGG analysis of the genes in the turquoise module. KEGG, Kyoto Encyclopedia of Genes and Genomes.](ol-18-06-6066-g04){#f5-ol-0-0-10961}

![Protein-protein interaction network of genes in the black and turquoise modules. The size of the circle represents the degree of the node; lines indicate interactions between genes.](ol-18-06-6066-g05){#f6-ol-0-0-10961}

![Validation of the expression of hub genes in primary and metastatic melanoma using TCGA database. Expression levels of (A) CXCR4, (B) IL7R and (C) PIK3CG in primary and metastatic melanoma. (D-F) Survival analysis of the hub genes in TCGA dataset for (D) CXCR4, (E) IL7R and (F) PIK3CG. Red lines represent low expression of the hub genes; blue lines represent high expression. (G-I) Receiver operating characteristic curves and AUC statistics were calculated to evaluate the capacity of distinguishing primary and metastatic melanoma of (G) CXCR4, (H) IL7R and (I) PIK3CG. TGCA, The Cancer Genome Atlas; CXCR4, C-X-C motif chemokine receptor 4; IL7R, interleukin 7 receptor; PIK3CG, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit γ; AUC, area under the curve.](ol-18-06-6066-g06){#f7-ol-0-0-10961}

![Drug-gene interaction network. Network analysis of hub genes and their target drug networks in melanoma. Purple squares represent predicted drugs that may treat melanoma, pink dots are drug targets, green dots are genes associated with tumor development that are also drug targets, and gray dots are genes associated with tumor development that are not targets of drugs. A purple line indicates an interaction between a drug and a target, and a gray line indicates an interaction between genes.](ol-18-06-6066-g07){#f8-ol-0-0-10961}

###### 

Summary of number and corresponding GSM in GSE65904.

  Number   GSM
  -------- ------------
    1      GSM1608593
    2      GSM1608594
    3      GSM1608595
    4      GSM1608596
    5      GSM1608597
    6      GSM1608598
    7      GSM1608599
    8      GSM1608600
    9      GSM1608601
  10       GSM1608602
  11       GSM1608603
  12       GSM1608604
  13       GSM1608605
  14       GSM1608606
  15       GSM1608607
  16       GSM1608608
  17       GSM1608609
  18       GSM1608610
  19       GSM1608611
  20       GSM1608612
  21       GSM1608613
  22       GSM1608614
  23       GSM1608615
  24       GSM1608616
  25       GSM1608617
  26       GSM1608618
  27       GSM1608619
  28       GSM1608620
  29       GSM1608621
  30       GSM1608622
  31       GSM1608623
  32       GSM1608624
  33       GSM1608625
  34       GSM1608626
  35       GSM1608627
  36       GSM1608628
  37       GSM1608629
  38       GSM1608630
  39       GSM1608631
  40       GSM1608632
  41       GSM1608633
  42       GSM1608634
  43       GSM1608635
  44       GSM1608636
  45       GSM1608637
  46       GSM1608638
  47       GSM1608639
  48       GSM1608640
  49       GSM1608641
  50       GSM1608642
  51       GSM1608643
  52       GSM1608644
  53       GSM1608645
  54       GSM1608646
  55       GSM1608647
  56       GSM1608648
  57       GSM1608649
  58       GSM1608650
  59       GSM1608651
  60       GSM1608652
  61       GSM1608653
  62       GSM1608654
  63       GSM1608655
  64       GSM1608656
  65       GSM1608657
  66       GSM1608658
  67       GSM1608659
  68       GSM1608660
  69       GSM1608661
  70       GSM1608662
  71       GSM1608663
  72       GSM1608664
  73       GSM1608665
  74       GSM1608666
  75       GSM1608667
  76       GSM1608668
  77       GSM1608669
  78       GSM1608670
  79       GSM1608671
  80       GSM1608672
  81       GSM1608673
  82       GSM1608674
  83       GSM1608675
  84       GSM1608676
  85       GSM1608677
  86       GSM1608678
  87       GSM1608679
  88       GSM1608680
  89       GSM1608681
  90       GSM1608682
  91       GSM1608683
  92       GSM1608684
  93       GSM1608685
  94       GSM1608686
  95       GSM1608687
  96       GSM1608688
  97       GSM1608689
  98       GSM1608690
  99       GSM1608691
  100      GSM1608692
  101      GSM1608693
  102      GSM1608694
  103      GSM1608695
  104      GSM1608696
  105      GSM1608697
  106      GSM1608698
  107      GSM1608699
  108      GSM1608700
  109      GSM1608701
  110      GSM1608702
  111      GSM1608703
  112      GSM1608704
  113      GSM1608705
  114      GSM1608706
  115      GSM1608707
  116      GSM1608708
  117      GSM1608709
  118      GSM1608710
  119      GSM1608711
  120      GSM1608712
  121      GSM1608713
  122      GSM1608714
  123      GSM1608715
  124      GSM1608716
  125      GSM1608717
  126      GSM1608718
  127      GSM1608719
  128      GSM1608720
  129      GSM1608721
  130      GSM1608722
  131      GSM1608723
  132      GSM1608724
  133      GSM1608725
  134      GSM1608726
  135      GSM1608727
  136      GSM1608728
  137      GSM1608729
  138      GSM1608730
  139      GSM1608731
  140      GSM1608732
  141      GSM1608733
  142      GSM1608734
  143      GSM1608735
  144      GSM1608736
  145      GSM1608737
  146      GSM1608738
  147      GSM1608739
  148      GSM1608740
  149      GSM1608741
  150      GSM1608742
  151      GSM1608743
  152      GSM1608744
  153      GSM1608745
  154      GSM1608746
  155      GSM1608747
  156      GSM1608748
  157      GSM1608749
  158      GSM1608750
  159      GSM1608751
  160      GSM1608752
  161      GSM1608753
  162      GSM1608754
  163      GSM1608755
  164      GSM1608756
  165      GSM1608757
  166      GSM1608758
  167      GSM1608759
  168      GSM1608760
  169      GSM1608761
  170      GSM1608762
  171      GSM1608763
  172      GSM1608764
  173      GSM1608765
  174      GSM1608766
  175      GSM1608767
  176      GSM1608768
  177      GSM1608769
  178      GSM1608770
  179      GSM1608771
  180      GSM1608772
  181      GSM1608773
  182      GSM1608774
  183      GSM1608775
  184      GSM1608776
  185      GSM1608777
  186      GSM1608778
  187      GSM1608779
  188      GSM1608780
  189      GSM1608781
  190      GSM1608782
  191      GSM1608783
  192      GSM1608784
  193      GSM1608785
  194      GSM1608786
  195      GSM1608787
  196      GSM1608788
  197      GSM1608789
  198      GSM1608790
  199      GSM1608791
  200      GSM1608792
  201      GSM1608793
  202      GSM1608794
  203      GSM1608795
  204      GSM1608796
  205      GSM1608797
  206      GSM1608798
  207      GSM1608799
  208      GSM1608800
  209      GSM1608801
  210      GSM1608802
  211      GSM1608803
  212      GSM1608804
  213      GSM1608805
  214      GSM1608806

[^1]: Contributed equally
